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Isolation of secondary metabolites
For scale up, A. terreus wild type and knock-outs were cultivated at 30 °C on YAG plates (D = 15 cm, ~50 ml per plate, total volume = 2 liter) for 6 days. Agar was chopped into small pieces and then soaked in 2 L of 1:1 CH2Cl2/MeOH for 24 hrs. After filtration, the crude extract was evaporated in vacuo to yield a residue, which was then suspended in 500 ml water and partitioned with EtOAc (500 ml) three times. The EtOAc layer was discarded. The pH of the water layer was then adjusted to around 2 and extracted with EtOAc (500 ml × 2). The combined EtOAc layer was evaporated in vacuo to a crude extract.
Further purification was carried on by gradient HPLC on a C18 reverse phase column [Phenomenex Luna 5μm C18, 250 × 10 mm] with a flow rate of 5.0 ml/min and measured by a UV detector at 254 nm. The gradient system was MeCN (solvent B) S3 and 5% MeCN/H2O (solvent A) both containing 0.05% TFA.
The gradient condition for HPLC analysis of crude extract from WT was 0-2 min 100-80% A, 2-7 min 80-66% A, 7-27 min 66-54.8% A, 27-29 min 54.8-0% A, 29-31 min 0-100% A, 31-33 min 100% A. Compound 1 (28 mg/L) was eluted at about 5 min. The gradient condition for HPLC analysis of crude extracts from ATEG_06272.1Δ and ATEG_06274.1Δ was 0-5 min 100-80% A, 5-20 min 80-60% A, 20-25 min 60-0% A, 25-30 min 0-100% A, 30-35 min 100% A. Compounds 2 (16 mg/L) and 3 (5 mg/L) were eluted at 16.0 min and 6.5 min, respectively. The gradient condition for HPLC analysis of crude extract from ATEG_06277.1Δ was 0-5 min 100-80% A, 5-10 min 80% A, 10-12 min 80-0% A, 12-14 min 0% A, 14-16 min 0-100% A, 16-18 min 100% A. Compound 4 (7.5 mg/L) was eluted at 9.0 min.
Feeding compound 5 to atXΔ
The 3-methylcatechol (5) was bought from Sigma Aldrich. It was dissolved in DMSO and added to YAG medium when the medium's temperature dropped to around 50 °C after autoclaving. The atXΔ mutant was cultivated at 30 °C on YAG containing 0.2 mg/ml compound 5. The WT strain and the atXΔ mutant were also cultivated on ordinary YAG as control. After 6 days cultivation, the followed extraction and LC-MS analysis were similar as described above.
Spectral data of compounds HRESIMS spectra were obtained on an Agilent Technologies 1200 series high-resolution mass spectrometer. NMR spectra were collected on a Varian Mercury Plus 400 spectrometer.
Terreic acid (1), 6-methylsalicylic acid (2), terremutin (3) and (2E, 4Z)-2-methyl-2, 4-hexadienedioic acid (4). For UV-Vis and ESIMS spectra, see Figure S1 ; For NMR spectra, see Table S3 , S4, S5 and S6 respectively. The molecular formula of compound 4 was determined by HRESIMS to be C7H7O4 [M -H] -(m/z 155.0341, calcd for C7H7O4 155.0350). The NMR data of compounds 1, 2, 3 were in good agreement with the published data. Figure S1 . UV-Vis and ESIMS spectra of compounds 1 to 4 and unrelated compound (*). The molecular formula of the compound labeled with "*" was determined by HRESIMS to be C12H16NO5 [M -H] -(m/z 254.1035, calcd for C12H16NO5 254.1034). The compound labeled with "*" is not terreic acid (1) pathway related based on two evidence: (1). It can be detected in the atXΔ strain; (2). The HRESIMS predicted molecular formula suggests that the compound contains one nitrogen, but there is no nitrogen-bearing group identified in terreic acid (1) or any of the proposed intermediates in its pathway. S12 Figure S2 . Schematic of the diagnostic PCR strategy. We used two redundant strategies to determine if the target gene had been deleted by replacement with AfpyrG. In one strategy, DNA from transformants is amplified with two primers, P1 from the chromosomal region just outside of the 5' flank of the transforming DNA fragment and P6 from just outside of the 3' flank. If the target gene is different in size from the AfpyrG gene, which was used as a selectable marker for transformation, the PCR fragment amplified from a correct transformant (a) will be different in size from the fragment amplified if the target gene is intact (b). In some instances the target gene and the AfpyrG cassette will be of comparable size and a second strategy is applied. In the second strategy, P1 or P6 are used with internal primers specific to the AfpyrG cassette. For example, if the target gene has been replaced by the AfpyrG gene (c), P1 and AfpyrGR will amplify a fragment of a predictable size. If the target gene has not been replaced (d), the AfpyrGR primer will not anneal and there will be no specific amplification. Figure S3 . Results of diagnostic PCR for all the gene deletion strains. 
